" class="no-js "lang="en-US"> Adnan Sharif - Medtech Alert
Tuesday, August 26, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Adnan Sharif

Adnan Sharif

About Adnan Sharif

Experienced Nephrologist with a special interest in transplantation | University Hospitals Birmingham

Honorary Reader with interest in clinical and translational research | University of Birmingham

Trustee | Kidney Research UK

Trustee | Global Kidney Foundation

Secretary | Doctors Against Forced Organ Harvesting

Councillor | British Transplantation Society (2019-2022)

Related Story

Diseases

 The Scottish Medicines Consortium (SMC) Recommends Use of Hansa Biopharma’s Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients | Pharmtech Focus

The Scottish Medicines Consortium (SMC) Recommends Use of Hansa Biopharma’s Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

September 13 2022

Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, […]

Drug Development

 NICE Recommends Use of Hansa Biopharma's Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients | Pharmtech Focus

NICE Recommends Use of Hansa Biopharma's Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

June 16 2022

Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, today […]